JP-1302

JP-1302 is a potent and highly selective small molecule antagonist of the alpha-2C adrenergic receptor (α2C-AR). It was developed as a pharmacological tool to differentiate the functions of the three alpha-2 adrenoceptor subtypes (α2A, α2B, and α2C). Preclinical studies have demonstrated its potential in treating central nervous system disorders, showing antidepressant-like and antipsychotic-like activities in rodent models, particularly in alleviating cognitive deficits and social withdrawal. Additionally, JP-1302 has shown renoprotective effects in models of acute kidney injury and cisplatin-induced nephrotoxicity by reducing norepinephrine levels and suppressing the expression of pro-inflammatory cytokines like TNF-α and MCP-1. It is also investigated for its role in modulating cardiac sympathetic tone and pain processing.

Other names

JP1302JP-1302JP 1302